Just a few days after President Trump called Regeneron a coronavirus cure, researchers at UW Medicine and the Fred Hutchinson Cancer Research Center have decided to begin testing the medicine.
The researchers are hoping to test monoclonal antibodies created by Regeneron Pharmaceuticals to prevent coronavirus and are currently in the phase of recruiting patients.
“Monoclonal antibodies are very promising,” said co-principal investigator Dr. Ruanne Barnabas, associate professor of global health and allergy and infectious diseases at the University of Washington School of Medicine, in a news release.
- See also:
According to the University of Washington, monoclonal antibodies are intended to provide immediate antiviral activity that lasts several weeks. UW Medicine’s AIDS Clinical Trial Unit is already conducting a treatment trial of other monoclonal antibodies.
During the Regeneron study, the scientists will be testing a double antibody cocktail called REGN-COV2 (REGN10933+REGN10987), which “had favorable results in mouse models and a positive review of the Phase I safety evaluation in an initial cohort of 30 hospitalized and non-hospitalized patients with COVID-19.”
Those interested in participating in the prevention study must have a confirmed household member test positive for SARS-CoV-2, the virus that causes coronavirus.
Participation involves at least 10 in-person follow-up visits that will include collection of blood and respiratory swab samples, medical history, and exams. Participants will need to monitor and report their symptoms and temperature.